Inflammatory cytokines in bladder cancer

被引:38
作者
Shadpour, Pejman [1 ]
Zamani, Mojtaba [2 ]
Aghaalikhani, Nazi [3 ,4 ,5 ]
Rashtchizadeh, Nadereh [3 ,4 ,5 ]
机构
[1] IUMS, HMRC, HKC, Tehran, Iran
[2] Univ Tehran, Sch Agr, Dept Agron & Plant Breeding, Karaj, Iran
[3] Tabriz Univ Med Sci, Drug Appl Res Ctr, Tabriz, Iran
[4] Tabriz Univ Med Sci, Fac Med, Dept Biochem, Tabriz, Iran
[5] Tabriz Univ Med Sci, Fac Med, Clin Labs, Tabriz, Iran
关键词
bladder cancer; cytokines; inflammation; microenvironment; receptors; TUMOR-NECROSIS-FACTOR; BACILLUS-CALMETTE-GUERIN; TRANSITIONAL-CELL CARCINOMA; MESSENGER-RNA EXPRESSION; T-CELLS; URINARY INTERLEUKIN-8; GROWTH-FACTOR; NITRIC-OXIDE; TNF-ALPHA; SERUM INTERLEUKIN-18;
D O I
10.1002/jcp.28252
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
The presence of inflammatory cells and their products in the tumor microenvironment plays a crucial role in the pathogenesis of a tumor. Releasing the cytokines from a host in response to infection and inflammation can inhibit tumor growth and progression. However, tumor cells can also respond to the host cytokines with increasing the growth/invasion/metastasis. Bladder cancer (BC) is one of the most common cancers in the world. The microenvironment of a bladder tumor has been indicated to be rich in growth factors/inflammatory cytokines that can induce the tumor growth/progression and also suppress the immune system. On the contrary, modulate of the cancer progression has been shown following upregulation of the cytokines-related pathways that suggested the cytokines as potential therapeutic targets. In this study, we provide a summary of cytokines that are involved in BC formation/regression with both inflammatory and anti-inflammatory properties. A more accurate understanding of tumor microenvironment creates favorable conditions for cytokines targeting to treat BC.
引用
收藏
页码:14489 / 14499
页数:11
相关论文
共 136 条
[1]   Inflammation and esophageal carcinogenesis [J].
Abdel-Latif, Mohamed M. M. ;
Duggan, Shane ;
Reynolds, John V. ;
Kelleher, Dermot .
CURRENT OPINION IN PHARMACOLOGY, 2009, 9 (04) :396-404
[2]   Signalling pathways of the TNF superfamily: A double-edged sword [J].
Aggarwal, BB .
NATURE REVIEWS IMMUNOLOGY, 2003, 3 (09) :745-756
[3]   Targeting Inflammatory Pathways for Prevention and Therapy of Cancer: Short-Term Friend, Long-Term Foe [J].
Aggarwal, Bharat B. ;
Vijayalekshmi, R. V. ;
Sung, Bokyung .
CLINICAL CANCER RESEARCH, 2009, 15 (02) :425-430
[4]   Cytokine gene polymorphisms are associated with risk of urinary bladder cancer and recurrence after BCG immunotherapy [J].
Ahirwar, Dinesh K. ;
Agrahari, Anita ;
Mandhani, Anil ;
Mittal, Rama D. .
BIOMARKERS, 2009, 14 (04) :213-218
[5]  
Al-Biaty H. S. J., 2018, IRAQI J CANC MED GEN, V8, P31
[6]   Preoperative plasma levels of interleukin-6 and its soluble receptor predict disease recurrence and survival of patients with bladder cancer [J].
Andrews, B ;
Shariat, SF ;
Kim, JH ;
Wheeler, TM ;
Slawin, KM ;
Lerner, SP .
JOURNAL OF UROLOGY, 2002, 167 (03) :1475-1481
[7]   Interleukin-1 receptor antagonist: Role in biology [J].
Arend, WP ;
Malyak, M ;
Guthridge, CJ ;
Gabay, C .
ANNUAL REVIEW OF IMMUNOLOGY, 1998, 16 :27-55
[8]   Physiologic role of interleukin-1 receptor antagonist [J].
Arend, WP ;
Gabay, C .
ARTHRITIS RESEARCH, 2000, 2 (04) :245-248
[9]   Increased Interleukin-17 Transcripts in Peripheral Blood Mononuclear Cells, a Link Between T-Helper 17 and Proinflammatory Responses in Bladder Cancer [J].
Baharlou, Rasoul ;
Khezri, Abdolaziz ;
Razmkhah, Mahboobeh ;
Habibagahi, Mojtaba ;
Hosseini, Ahmad ;
Ghaderi, Abbas ;
Jaberipour, Mansooreh .
IRANIAN RED CRESCENT MEDICAL JOURNAL, 2015, 17 (02)
[10]  
Baharlou Rasoul, 2014, Immune Netw, V14, P156, DOI 10.4110/in.2014.14.3.156